Skip to main content
PLOS One logoLink to PLOS One
. 2023 Feb 22;18(2):e0281984. doi: 10.1371/journal.pone.0281984

Acceptability of PrEP among MSM and transgender communities—Qualitative findings from two metropolitan cities in India

Satyanarayana Ramanaik 1,*, Anju Pradhan Sinha 2, Aparna Mukherjee 1, Ashwini Pujar 1, Kalyani Subramanyam 3, Anjali Gopalan 3, Reynold Washington 4,5
Editor: Peter A Newman6
PMCID: PMC9946201  PMID: 36812258

Abstract

Background

Global evidence suggests that Pre-Exposure Prophylaxis (PrEP) plays a pivotal role in reducing new HIV-infections among key populations (KP). However, the acceptability of PrEP differs across different geographical and cultural settings and among different KP typologies. Men who have sex with men (MSM) and transgender (TG) communities in India have around 15–17 times higher prevalence of human immunodeficiency virus (HIV) than the general population. The low rates of consistent condom use and poor coverage of HIV testing and treatment among the MSM and transgender communities highlight the need for alternative HIV prevention options.

Methods

We used data from 20 in-depth interviews and 24 focused group discussions involving 143 MSM and 97 transgender individuals from the two metropolitan cities (Bengaluru and Delhi) in India to qualitatively explore their acceptability of PrEP as a HIV prevention tool. We coded data in NVivo and conducted extensive thematic content analysis.

Results

Awareness and use of PrEP were minimal among the MSM and transgender communities in both cities. However, on being provided with information on PrEP, both MSM and transgender communities expressed willingness to use PrEP as an additional HIV-prevention tool, to complement inability to consistently use condoms. PrEP was also perceived as a tool that could enhance the uptake of HIV-testing and counseling services. PrEP awareness, availability, accessibility and affordability were identified as determining factors that could influence its acceptability. Challenges such as stigma and discrimination, interrupted supply of drugs and non-community-friendly drug dispensing sites were identified barriers to continuing PrEP.

Conclusions

Using qualitative data from two Indian settings, this study provides community perspectives and recommendations to stakeholders and policymakers for introduction of PrEP into programs as a prevention tool among MSM and transgender communities in India.

Introduction

Globally, the number of people newly infected or dying due to HIV and AIDS have reduced in recent years. Yet, with a global HIV prevalence of 0.8%, an estimated 37.9 million people were living with HIV in 2018 [1, 2]. Low and middle-income countries bear most of this burden. India has the third-largest HIV epidemic in the world, with 2.3 million people estimated to be living with HIV [3]. An estimated 63000 new HIV infections occurred in 2021, a 37% decrease since 2010. AIDS-related mortality is estimated at 4.43 per 100,000 population in 2019, a decline from its peak of 25 per 100,000 during 2004/05 [4]. Although India’s HIV prevention, testing and treatment efforts have resulted in substantial declines in HIV prevalence, the coverage of key populations with critical interventions remains sub-optimal [5]. Key populations (KPs) including female sex workers (FSW), men who have sex with men (MSM), transgender communities (TG), and persons who inject drugs (PWID) remain vulnerable to HIV infection. Interventions with KPs require a more nuanced understanding of their health needs and their socio-environmental contexts.

In India, MSM and the transgender community are at greater risk of HIV infection compared to the general population [6]. HIV prevalence among MSM (3.3%) and transgender community (3.8%) is about 15 to 17 fold higher than the general population (0.22%) [3, 7]. Despite national efforts to ensure their health rights and wellbeing, they continue to face substantial structural and interpersonal barriers while accessing HIV prevention and care services [8].

MSM and transgender communities are biologically, socially, and structurally more vulnerable to HIV. The taboo against their gender identity, the social stigma and discrimination that these populations face and their discrete behaviors within society make it challenging to design and implement HIV prevention interventions that enable access to essential HIV prevention services [9, 10]. Moreover, studies show that inconsistent condom use, frequent alcohol use, experiences of sexual violence and engagement with multiple concurrent partners among both the MSM and transgender communities raise their risk for HIV [11, 12]. Experiences of sexual violence among MSM and TG communities puts them at a much higher risk of HIV [13, 14]. It is therefore essential to provide other forms of prevention that can address these key populations’ risk context in a manner that is culturally appropriate and customized to their concerns. One such option is the use of Pre-Exposure Prophylaxis (PrEP) as a HIV prevention method. PrEP is a valuable opportunity to implement effective HIV prevention interventions among MSM and transgender communities [1]. Recent trials and feasibility studies on PrEP around the world have shown promising results among the transgender communities, MSM, and Female Sex Workers (FSW) [1517] with evidence pointing out that consistent and correct use of PrEP can significantly reduce the chances of HIV infection [18].

It is therefore important to explore whether KPs are willing and able to adopt and adhere to prescribed regimens of PrEP. Literature on the acceptability of PrEP among MSM and transgender communities in India is limited. It was in this context that the Indian Council for Medical Research (ICMR) task force on HIV Prevention commissioned a study, that was implemented by St. John’s Research Institute in partnership with Karnataka Health Promotion Trust (KHPT), Bengaluru and the Naz Foundation, Delhi. The study aimed to understand the barriers and enablers to acceptance of PrEP as a prevention tool among the MSM and transgender community. This study also explored community perceived solutions and conditions in two culturally different contexts that would be required for rolling out PrEP programs in India.

Methodology

Study design and sample

This qualitative study explored the perspectives of MSM and transgender communities to their acceptability of PrEP. Focus Group Discussions (FGDs) were used to explore the participants knowledge and perspectives on PrEP, feasibility for regular use, potential challenges with regular use, and processes by which programs could popularize or roll out PrEP in order to enhance acceptance by the community. In-depth interviews (IDI) were also conducted to gain a deeper understanding of more specific and personal issues such as condom use, HIV testing, and interpersonal dynamics within the MSM and transgender communities in the two study sites in India. The study was conducted in two major metropolitan cities, New Delhi and Bengaluru, between July 2017 and June 2018. The Naz Foundation, New Delhi and the Karnataka Health Promotion Trust (KHPT), Bengaluru, were involved in study implementation.

Purposive sampling was used to recruit eligible participants. Eligible participants included distinct types of MSM and transgender communities. MSM refers to self-identified gay men (western acculturated), kothis (men who tend to be the receptive male partner in anal and oral sex and typically have more feminine mannerisms), panthis (men who tend to be the insertive male partner in anal and oral sex), and double-deckers (men who are both receptive and insertive partners) [19]. Transgender women were those who reported male at birth but self-identify as women or female. Transgender community are broadly categorized as transgender Hijras and transgender non-Hijras [20, 21]. All participants were in the age group of 18–45 years and provided written consent to participate in the study. In total, 20 IDIs (Bengaluru 11 and Delhi 9) and 24 FGDs (Bengaluru 12 and Delhi 12) with 220 total participants were completed in about six months, starting from September 2017 to February 2018. Local community-based organizations who were implementing targeted intervention programs under the National AIDS Control Program, were involved in mobilizing participants. Both FGDs and IDIs were conducted in places where the participants felt safe and comfortable and included Community Based Organization/Non-Government Organization (CBO/NGO) offices and field-level clinics.

Subsequent to posing the initial questions on PrEP knowledge, interviewers provided basic PrEP information to all participants, including the composition of PrEP, the mechanism by which PrEP works for HIV prevention, the dosage required, its availability and cost in India, in simple non-medical language. The information provided participants with knowledge to respond to questions on the usefulness and acceptability of PrEP by the community.

Study tools and data analysis

We used independently developed and pre-tested semi-structured interview guides for both IDI and FGDs. The tools contained questions to assess the participants’ knowledge and risk perception of HIV/AIDS, views and perception on PrEP, and knowledge and utilization of preventive interventions that were currently offered within the targeted intervention programs. Extensive probes were used to elicit additional information on each theme. In addition to participating in the interviews, we asked participants to complete HIV service mapping activities. These intervention maps provided us with a wealth of information about the population’s knowledge of services that were accessible to them and the geographical or social implications of current service locations that could potentially offer PrEP services. We trained interviewers from both the sites over two days. Most interviewers had previous experience of conducting qualitative studies. The training included research ethics, study objectives, qualitative research methods, and aspects on PrEP.

The field teams transcribed all 24 FGDs and 20 IDI from Bengaluru and Delhi sites. Field supervisors verified the verbatim (audio to regional languages) transcription documents for accuracy and completeness. Subsequently, the team translated all transcripts into English. We used NVivo-11 to assist qualitative data management and analysis [22]. We held a consultation workshop with field investigators from both sites in order to develop the analytical framework. The thematic content analysis was supplemented by constant comparison and deviant case analysis techniques.

Ethical considerations

We obtained written informed consent from all study participants for their voluntary participation and audio recording of the interviews. We maintained anonymity by using a unique study ID to distinguish individual participants in the study. While presenting our findings in this paper, we use pseudonyms. The Institutional Ethics Committee of St. John’s Medical College and Hospital, Bengaluru (Ref # 92/2014) approved this study. In consideration of the potential risks of disclosure of the study subject’s identity, we took extra measures to secure and de-identify the documents. During the training, we briefed the data collectors about the sensitivity of the subject and the necessity for discretion and privacy regarding personal identifying information.

Results

We present awareness, acceptability, concerns around use and community’s suggestions on the most appropriate methods to roll out PrEP programs.

Profile of the participants

A total of 143 MSM and 97 transgender individuals were involved across both sites. The socio-demographic characteristics of the participants are listed in Table 1.

Table 1. Sociodemographic characteristics of MSM and transgender communities in IDI and FGD (n = 240).

Characteristics MSM transgender community Total n = 240 (%)
n = 143 (%) n = 97 (%)
Age
    >25 44 (30.76) 43 (44.32) 87 (36.25)
    26–40 75 (52.44) 49 (50.51) 124 (51.66)
    40+ 24 (16.78) 5 (5.15) 29 (12.08)
Highest level of education completed
    No formal education 11 (7.69) 7 (7.21) 18 (7.05)
    Primary 24 (16.78) 21 (21.64) 45 (18.75)
    High school 56 (39.16) 39 (40.20) 95 (39.58)
    College 52 (36.36) 30 (30.92) 82 (34.16)
Primary Identity 
    Kothi 68 (47.55) 0 68 (28.33)
    DD 58 (40.55) 0 58 (24.16)
    Bi-sexual 7 (4.89) 0 7 (2.91)
    Panthi 6 (4.19) 0 6 (2.05)
    Gay 4 (2.79) 0 4 (1.66)
    Hijra Identified 0 94 (96.90) 94 (39.16)
    Trans Identified 0 3 (3.09) 3 (1.25)
Marital Status
    Married 53 (37.06) 10 (10.30) 63 (26.25)
    Unmarried 86 (60.13) 84 (86.59) 170 (70.83)
    Divorced/separated 4 (2.79) 3 (3.09) 7 (2.91)
Main Occupation
    Sex work 20 (13.98) 25 (25.77) 45 (18.75)
    Daily wage labour 45 (31.46) 31 (31.95) 76 (31.66)
    Works at CBO 14 (9.79) 5 (5.15) 19 (7.91)
    Private 20 (13.98) 9 (9.27) 29 (12.08)
    Business 6 (4.19) 0 6 (2.05)
    Unemployed 5 (3.49) 0 5 (2.08)
    Toli Badhai/begging 0 15 (15.46) 15 (6.25)
    Not disclosed 33 (23.07) 12 (12.37) 45 (18.75)

Awareness about PrEP

For a majority of the participants, the first introduction to PrEP was during this study.

Is PrEP useful for HIV positive people or only HIV negative people? How soon will PrEP provide protection? Can we take the PrEP medicines in conjunction with other medications? (Sandesh, MSM, 29 years, Bengaluru).

Their limited information had been previously gathered during informal interactions, rather than formal PrEP educational sessions.

I have only heard about the tablet’s name. Nobody in the community has explained or told me about this (Anand, MSM, 30 years, Bengaluru).

In both Delhi and Bengaluru sites, transgender communities displayed a better understanding of PrEP as compared to the MSM group and sources of information included peer networks, internet and social media, or non-government organizations. In Bengaluru, transgender individuals who had heard of PrEP were not sure about its availability in India, its cost, how it was to be consumed or its effect on HIV prevention. Few participants from both the communities misunderstood PrEP to be PEP (post-exposure prophylaxis).

The researchers responded to questions before further probing on perspectives towards PrEP acceptability.

How can PrEP benefit your community?

In both Delhi and Bengaluru, the transgender and MSM participants felt that PrEP could be very beneficial as it could provide “double protection” to them. Both groups also found it useful in instances when the condom slips off or tears.

We can control HIV/AIDS by consuming the PrEP tablets. Similarly, we could control STI’s by using condoms externally. Both are good to safeguard our health. Sometimes, if we are going ahead in our sexual interaction even without condoms also, we would feel safe and confident… we will not be infected with HIV if the condom breaks/pops/slips off… (Rupa, transgender individual, 29 years, Delhi).

The MSM population felt that PrEP had an additional benefit to them as medicines could be consumed without fear of being judged by others, whereas carrying condoms to the home could raise suspicions from family members.

Female or male, they can’t carry the condoms in their pocket or bags. If someone in our household came to know that we have condoms, then there will be fights in the homes. If there are tablets, then people won’t suspect much…. If such kind of a tablet is introduced, then it will be good. (Sourav, MSM, 34 years, Delhi).

If we start consuming pills on a daily basis, the family members could inquire about the reason for consuming those tablets. Mothers would be always the first person to inquire about them. Whether for fever or any other health ailments. We might be able to keep it confidential from anybody but to keep it so private from mother or others would be very difficult. We might still go ahead in saying something like vitamin tablets, etc., but we can’t do so for a longer period. (Janardhan, Bisexual, 48 years, Bengaluru).

Few participants expressed a view that PrEP could reduce the frequency for HIV testing. The transgender communities reported that PrEP could be particularly relevant when they desired more intimate relationships with their partners or when their clients did not agree to use condoms. During forced sex or coercion, PrEP could offer them protection from HIV infection.

Sometimes telling them (clients) to use condoms is difficult and in such situations, taking this pill gives more freedom from tension. (Preeti, transgender individual, 26 years, Bengaluru).

Non-panthi MSM and transgender individuals perceived that Panthis were largely responsible for HIV transmission. They would often coerce or trick partners into abandoning condoms. Panthis have been known to take condoms off before or during intercourse, without their partner’s knowledge. They threaten partners who insist on condom use, or intentionally damage condoms such that they tear during intercourse. Their stories suggest that condoms are not an effective HIV prevention option among non-panthi MSM and transgender individuals. Male Sex Workers (MSW) in the group are often offered more money to forgo condoms. Poverty and deprivation often force them to concede to their customer’s demands. Clients were known to become violent if MSW refuse sex without a condom and the interactions usually end up with violence, including rape. These power dynamics within the community adversely influence the effectiveness of condoms for HIV prevention. Participants expressed that they would be at lower risk of HIV infection with PrEP.

I know that our community participates in sex work and carries condoms. Sometimes in hamams they have more than 20–30 clients a day. It is exhausting and they may not have much patience to wear the condom properly, to check whether there is air inside or not and she may be not much cautious about the breakage and all so, therefore, the tablet will be helpful. (Preeti, transgender individual, 26 years, Bengaluru).

One more major identified barrier to condom use was alcohol and substance abuse. Many participants stated that when they were under alcohol influence, it became difficult to use a condom. MSW shared that clients who drank or took drugs were often vehemently opposed to using condoms.

Those customers/clients who do approach us under the influence of alcohol/drinks, we find very difficult. We find it very difficult for those who are not in their true senses because of their addiction of drugs/narcotics. Whatever ways we try to convince them, it would be futile and they don’t listen to our request. (Keerthi, transgender individual, 36 years, Bengaluru).

Also, the issue of using inappropriate lubricants was reflected in both MSM and transgender communities’ interviews. Many participants reported difficulty in finding gels or other approved sexual lubricants. In the absence of gel, participants reported that community members use substitutes such as cooking oil, lotion, or coconut oil. These substitutes are preferred because they are easily available, affordable, and do not suggest ‘socially tabooed’ behavior. However, oil-based solutions are not appropriate for use as a sexual lubricant. Many of the participants knew that oil-based lubricants compromise the integrity of condoms, leading to condom breakage or tears during intercourse, but yet admitted that these substitutes are sometimes used even without a condom to reduce friction and pain and to increase pleasure during sexual intercourse.

Most of the MSM and transgender communities were keen that PrEP messaging should be communicated to other high-risk communities including FSWs and PWID. The network between high-risk communities is complex. Therefore, providing information and education on PrEP to MSM and transgender communities alone may not be sufficient. It is important to consider all high-risk communities while designing PrEP rollout programs in the country. Educating the general community, especially the youths, will not just help to protect them from HIV, but will also reduce stigma and discrimination attached to the key populations in India.

I think all communities will benefit. Everyone wants to be safe. I understand why the focus is on my community, my community is at high risk with multiple partners, into alcohol and they maintain secrecy. This way they are more at risk of getting infected by HIV (Kajal, transgender individual, 34 years, Delhi).

Our results indicate that both in Delhi and Bengaluru and among both MSM and transgender communities, a need to have alternative HIV protection methods such as PrEP was useful. However, mild differences existed in the perceived reasons for PrEP use. The transgender communities largely perceived that PrEP would offer them HIV protection despite their compromised decision-making and frequent encounter of violence during sexual interactions. However, among the MSM, their major concern was secrecy from the family and society about their sexual identity, with PrEP offering an alternative to the challenges around condom-use within their homes.

Concerns over the use of PrEP

Results from both sites, and across typologies, elicited different factors that could impact the acceptability of PrEP. All participants expressed their concerns about making PrEP easily and consistently available in India. They pointed out that there were major interruptions with regular supply of condoms and antiretroviral treatment (ART) that occurred with changing program leadership and supply chain issues. Even large hospitals often faced shortage of HIV prevention and treatment materials and supplies. Often in the past, ART drugs were withdrawn from their communities, when different political parties came into power. They were concerned that similar lack of consistent availability could arise with PrEP and that this could lead to drug-resistant strains developing within the community.

Sometimes the present government may start providing the tablets. Then if we have the next government they may stop or not give it on time. (Rahim, Kothi, 27 years, Bengaluru).

The high costs of PrEP was also expressed as an important concern by both the MSM and transgender communities in both the study sites. Many participants said, a large number of MSM and transgender communities engage in sex work to fulfill their financial needs and though they understand they are at increased risk to contract HIV, the potential cost associated with using PrEP was a deterrent to its use. Participants were also concerned that the additional lab tests prior to and during PrEP would be exorbitant in cost and beyond their means.

Earning money is itself very tough … therefore if they are being distributed free of cost it would be preferable. (Ranga, Kothi, 32 years, Bengaluru).

Many members of the MSM and transgender communities spoke about facing stigma and discrimination when they venture into public spaces and in health care settings. Many participants reported being treated disrespectfully within government hospitals.

I was facing a lot of problems when I go to health care facilities. Lots of discrimination, verbal discrimination, and nonverbal discrimination. I become very emotional and I suffered from depression because of it. I am afraid when I go to public places. (Preeti, transgender individual, 26 years, Bengaluru).

MSM, who were not outwardly identifiable, stated that they often felt judged when they divulged that they engaged in risky behavior with other men. Transgender communities, who are unable to hide their diversity from what is considered sociably acceptable, stated that they face discrimination as soon as they enter facilities. When they are assigned to a physician or a nurse, the provider often refuses to touch them or to do a thorough or complete physical or clinical examination. Some transgender communities shared that they often have longer waiting times than other patients and are often sent away from facilities without receiving services, or given rushed and incomplete services in an effort to dismiss them quickly. They also reported instances of being sent to various other facilities for simple or routine tests. Participants were concerned about how these issue would be resolved when PrEP is made available. For these and other reasons, participants prefer to go to the private hospitals, which are nearer to their residence and open for longer hours. They have built a better rapport with private hospital doctors, which also have functional equipment and regular supplies to perform all tests in one place. Another concern raised was the side effect of the medicines and the risk associated with prolonged use.

When you told me this tablet has to be consumed every-day, I was only thinking of side effects and drug resistance. (Pradeep, MSM, 30 years, Bengaluru).

MSM expressed concerns over additional side effects of PrEP when taken along with alcohol. Transgender communities were concerned that PrEP could negatively affect their bone density and create bone-related problems as they age, as many of them are on Hormone Replacement Therapy, which has a similar effect on bone density. Transgender communities in Bengaluru, also shared their concerns about side effects of PrEP, as many of them were already taking medicines for diabetes and blood pressure. They insisted that PrEP should be customized such that it is indicated only whenever they need it, that is before the sexual encounter.

All participants stated that many people may confuse PrEP with ART because both are daily regimens. This confusion can cause PrEP users to experience discrimination and community isolation, similar to the experience of persons living with HIV (PLHIV) who are on ART. This issue prompted participants to ask about possibilities of intermittent PrEP, or formulations of PrEP in the guise of a general health tonic, or for other PrEP formulations that would not necessitate daily consumption.

When we take them every day, they [family member] will relate it to ART and suspect that we are having HIV… so our people start looking at us differently. (Preeti, transgender individual, 26 years, Bengaluru).

Hijra transgender communities were concerned that their frequent travel could pose barriers to PrEP adherence. Hijras travel a lot to perform religious ceremonies and sometimes visit their rural homes and feared that they could run out of PrEP supplies and would be unable to get a timely refill in their villages. They expressed apprehensions that missing PrEP doses would lead to drug-resistant strains. They also shared that Hijras and Male Sex Workers’ late working hours and alcohol consumption could pose barriers to adherence.

Some of our people can’t consume it daily because they drink alcohol….Our community thinks that those who are taking the tablet daily, they suffer AIDS or TB, or any other serious infection. (Rehana, transgender individual, 30 years, Bengaluru).

Many MSM and transgender individuals participate in sex work intermittently. They said that it would be difficult for them to plan ahead and start the medicine 6 days prior to initiation of sexual activity and therefor preferred condoms as they were readily available and familiar to use.

How can PrEP be made available to MSM and transgender communities in India?

We enquired what community-friendly measures could be used to popularize and roll out PrEP in India. The first and foremost priority mentioned was to educate MSM and transgender communities on PrEP. All participants expressed interest to learn more about PrEP and were willing to share their knowledge with their peers. Discrete education methods using social media platforms like SMS, WhatsApp or Facebook were preferred options for the privacy and safe space that they offered.

We should advertise, through public media and social media like Facebook and WhatsApp, everywhere we should spread the messages (Uma, Kothi, 22 years, Bengaluru).

Transgender communities in Delhi also suggested that information could be provided at Hamams (their workplace). Participants who were in favor of learning in a safe space also suggested that NGOs and CBOs who work with these communities could begin PrEP education campaigns. However, married and bisexual participants pointed out that they rarely visit the CBO or NGO offices.

If the initiations are taken through our CBO, then the majority of our community people would be getting the information by verbal communication in more effective ways. There won’t be any problem in passing on the information with enthusiasm and happiness. (Girish, Panthi, 40 years, Bengaluru).

Similar to other ways of sharing information through radio, television, from friends working in NGOs, etc. (Manish, Panthi, 30 years, Delhi).

Some participants were in favor of widespread PrEP education campaigns that included general population and youth. Information, education and communication (IEC) materials such as flipcharts, brochures, pamphlets may be very useful in schools and colleges, government hospitals (only Kothis mentioned this), mobile platforms, and social media. Street-plays, drama and education campaigns could also reflect on PrEP.

With regards to affordability, most of our participants suggested that PrEP should be offered free of cost, just like free condoms that the government offers. This could be the government incentive to encourage PrEP use by the MSM/ transgender community. However, few opined that a nominal price could be charged to discourage its misuse, as free supply diminishes the perceived value of medicines and are liable to be discarded. Noteworthy is the fact that many of the participants in this study recruited were from a lower socioeconomic status. Most participants suggested that if there is a cost, it should be low enough to be affordable, at about Rs 5-10/- per month. Those from upper economic strata were willing to pay up to Rs 500/- per month.

We earn by begging; we expect it to be in the range of Rs 5/- to Rs 10/- for a month. In that case, only, our community could afford the price. Or else we will end up discontinuing the medicine. (Reshma, transgender individual, 29 years, Bengaluru).

If you distribute free of cost, people could lose importance and someone could misuse or waste them also… If they pay, they would show some concern about them. (Kiran, Bisexual, 30 years, Bengaluru).

The third issue was accessibility. All participants agreed that PrEP should be made available in facilities that MSM and transgender communities can comfortably access. Suggested locations included NGO and CBO offices, urban health clinics (Mohalla clinics), private hospitals that serve and empathize with MSM and transgender communities, and other self-service condom distribution points that are currently accessible to this vulnerable population. Few transgender individuals in Delhi reported that they also prefer to receive it from a petty shops like paan shops, where they could simply pick it up in the disguise of purchasing some other item.

This tablet should be made available everywhere in the NGOs and clinics like mohalla because people avoid going to big hospitals as they think where will they wander around in those hospitals asking for tablets. So, if it’s available at Mohalla clinic it will be easy for us to take them. (Rohit, Gay, 32 years, Delhi).

Participants also reiterated that importance of sensitizing healthcare professionals and the general community to address the stigma and discrimination attached to the key populations in India.

When I go to the government hospital they ask us, “being a man you have sex with a man, are you not ashamed of it?” They ask like this. After seeing all these, I don’t like to go there. (Hema, transgender individual, 37 years, Bengaluru).

Finally, the study subjects was asked about their perceptions on PrEP as compared to condoms. Both positive and negative responses were received. A majority of participants expressed a need for both condoms and PrEP. Both MSM and transgender communities admitted that their lifestyle and occupation puts them at increased risk for contracting Sexually Transmitted Infections (STIs) and HIV. PrEP can offer protection against HIV when condoms cannot be used. In addition, condoms protect against many STI. Few participants preferred condoms to PrEP stating that they were already familiar with condom use and knew where to access them.

In Table 2 we summarize the similarities and differences in perspectives of MSM and transgender communities regarding their acceptability towards PrEP.

Table 2. Comparison between perspectives of MSM and transgender communities on PrEP acceptability.

MSM TRANSGENDER COMMUNITIES
Need (for alternative HIV preventive-PrEP) Difficult to carry condoms home (fear of suspicion among the family members, esp. in younger MSM or unmarried MSMs) Difficult to negotiate with clients/partners for condom use (Dominating partner, excessive alcohol use, the demand of intimacy)
Can’t buy lubricants Use of inappropriate lubricants
Preference for intimacy Preference for intimacy
PrEP knowledge A large number of MSM have poor knowledge of PrEP Few transgender individuals were better informed about PrEP
Storage Can’t store medicines at home May forget to carry while on travel
Taking medicines regularly may create suspicion among the family members Cannot always plan their sexual encounters beforehand due to the nature of the job
Side effects General concerns about the side effects of the PrEP drug Few were concerned about the side effects of the PrEP medicine on bone density, as they undergo hormone replacement therapy which already poses a risk for decreased bone density.
Continuous use may lead to drug resistance
Side effects of the medicine when taken with medicines for multiple comorbidities like diabetes and BP
Testing Discomfort with HIV testing as pre-requisite to initiate PrEP Discomfort due to their experiences of stigma and discrimination, as a result of which they do not access regular HIV testing
Cost Preferred a low cost ranging from Rs 30-500/- per month Preferred it for free, or a nominal price. Rs 5-10/- per month
Availability Preferred through CBOs or NGOs. Few also suggested it should be available at the pharmacist or ‘paan’ shops or on internet e-portals Preferred only through CBOs
Usage Preferred to combine both condoms and PrEP Preferred to combine both condom and PrEP
Preferred a syrup or tonic or one tablet taken on ‘event’ basis Preferred one tablet taken as an emergency pill

Discussion

Our study explores the perceptions on the use of PrEP as a HIV prevention method among MSM and transgender community in two cities, one each from north and south India. The study also explored opinions for the configuration of a potential program roll-out of PrEP that would enhance the acceptability to these communities. In recent years, there has been an increase in the number of studies on PrEP acceptability among transgender women and MSM in India [11, 12]. However, not all studies on PrEP acceptability have described and compared the differences in perceptions or reasons for these perceptions between MSM and transgender communities.

The study is unique as it highlights the barriers to access for HIV prevention services that transgender communities and MSM face. The study also provides in-depth insights into targeted strategies that can be adopted to ensure that PrEP acceptability and use is optimized, when a PrEP program is rolled out.

The generic version of PrEP was approved for use in India in 2016. Yet, it is not available through the public healthcare system or at a subsidized cost in the private sector. Presently, few private practitioners prescribe PrEP and this is available with physical and online pharmacies. The estimated number of PrEP users in India ranges between 1500–2000 [23]. Anecdotal evidence suggests that most current users of PrEP are educated MSMs, belonging to the higher socioeconomic groups [11].

Currently, HIV targeted interventions focus on condoms as the sole method for prevention of HIV among MSM and transgender communities in India. The test and treat option is implemented and treatment can reduce the risk of HIV transmission, but substantial proportions of MSM and transgender communities do not regularly access HIV testing. This study also found that a large number of participants were not able to use condoms during sexual interactions, similar to other studies [24]. Condom use is often compromised because of inability to negotiate its use, or the need for intimacy with their partner [12, 19]. The feminine identity, poverty and dependence on sex work as a major source of livelihood among the transgender communities and MSM, create a hierarchy in power dynamics with their clients, who are often masculine with greater power in decisions pertaining to condom use. Moreover, misconceptions like double bagging and the use of inappropriate lubricants raise other challenges with condom use [14, 25]. Under such circumstances, most participants expressed that PrEP could be a useful complementary method of HIV prevention. However, very few participants were aware about PrEP and its use, with awareness levels slightly higher among the transgender communities. For many of the participants, the first introduction to PrEP was through this study. Most of the participants were excited by the possibilities that PrEP could offer and expressed surprise that PrEP information was not already circulating within the community. A conclusion reached was that PrEP awareness campaigns are crucial to its acceptability. Other studies have also found large proportions (93 percent) of participants were not aware of and had never heard about PrEP [26]. However, once informed about PrEP, their willingness to use PrEP was extremely high (99%) [26]. Both MSM and transgender community asserted that they need complete information regarding side effects, long-term health complications, interactions with other medications, drug resistance, costs, and pre-requisite tests. Potential side effects of PrEP remain a major concern among the MSM and transgender communities, similar to other studies [27]. Other studies have also pointed out that more trials on intermittent and long-term PrEP are necessary to rule out the possible side effects [28, 29].

Similar to the findings of Chakrapani et al, MSMs in our study also raised concerns about storage of PrEP drugs at home [11]. Transgender communities, on the other hand, expressed apprehension because of their challenges in access when they regularly travel to other places for work. Other studies too have shown that PrEP acceptability depends on ‘event-driven’ needs and is preferred where one of the partners is HIV infected and daily intake was one of the biggest obstacles to PrEP use [16, 17].

Concerns around the cost of PrEP are real not only in our study but also in middle and high-income countries [30, 31]. Chandhiok et al noted that cost was a major barrier to initial commitment, while an increased willingness to pay for PrEP was seen among younger age groups [32]. Our study also highlighted the need for a steady supply of the PrEP drug similar to a study by Gomez and Harris [33].

A pre-requisite of initiating PrEP is to undergo regular HIV testing, to confirm a negative status. This implies that HIV testing services, PrEP and treatment should be supportive towards key populations. Similar to other studies, our study too points out that stigma and discrimination remains a significant barrier preventing sexual minorities, especially the transgender communities from accessing healthcare services. Eliminating discrimination in healthcare services is one of the priorities towards ensuring their rights [34, 35]. A better understanding of the various factors that influence sexual risk behaviors and disclosure practices among HIV-positive MSM and ‘hijras’ can help counselors, physicians, and peer educators in providing appropriate information and nonjudgmental counseling and clinical services. This would also help the policymakers to design specifically tailored approaches within HIV prevention programs, as recommended by others [11].

Involving CBOs in the distribution of PrEP is an effective way to increase acceptance [21]. Similarly, programs designed to reduce HIV incidence among the key population should be centered around community empowerment and basic human rights [3638]. The ‘PrEP continuum of care’ theory by Kelley et al., 2015 emphasizes awareness and subsequent willingness to initiate PrEP among those at highest risk for HIV infection as a necessary first step [31]. Various theories of acceptability, such as the ‘Health belief model’ that considers the perceived benefits and the perceived barriers, and the ‘diffusion of innovation theory’ that suggests use by a small proportion will enhance use by larger numbers of peers, reinforce this option of involving CBOs for PrEP programs. CBOs are already actively involved in addressing basic needs of transgender communities. Public health professionals and healthcare providers often expect transgender communities to account for their sexual and reproductive health when they are denied basic human rights including shelter, secure jobs and the ability to provide food. One cannot expect that they would prioritize purchasing PrEP over meeting these primary needs.

This study has some limitations. Firstly, the participants were asked to share their opinion on PrEP without giving them the product. None of the participants had ever used PrEP and their responses were based upon information provided by the research team. It is possible that information provided by research team members differed based on the setting and duration of interactions. Secondly, as a qualitative study with a relatively small sample size, generalizations certainly cannot be made beyond the participant groups.

Conclusion

This study demonstrates that PrEP is acceptable among MSM and transgender communities in India. However, conditions that ensure its regular availability and accessibility should be in place. We did not find much difference in acceptability between the two sites, but the barriers and challenges are different for transgender communities and MSMs. The strategies to advocate PrEP use should thus be contextualized for each community. PrEP education campaigns are necessary not only among MSM and transgender communities, but also for health care providers and the general population. PrEP accessibility increases when offered in places where MSM and transgender communities can access services without prejudice. Cost is a significant factor determining the acceptability of PrEP among MSM and transgender communities. PrEP needs to be ‘de-medicalized’ and offered in non-clinical settings, much like condoms. PrEP may be offered within a ‘package of services’, rather than as a stand-alone intervention, as it is complementary to existing prevention initiatives and is especially useful among those with high-risk behavior who have challenges to consistently use condoms. However, when the concerns and benefits of PrEP are evaluated from the perspectives of the transgender communities and MSMs, it is clear that unless all concerns related to uninterrupted availability in a stigma free environment and at an affordable cost are addressed, the likelihood of its acceptance remain slim.

Supporting information

S1 File

(DOCX)

Acknowledgments

We thank the member of MSM/transgender communities from both Bengaluru and Delhi for participating in the study and providing valuable information. We also acknowledge the support received from the Karnataka State AIDS Prevention Society and Community Based Organizations such as Samara, Samara society and Payana, Bengaluru and Community Empowerment Trust, Basera Samajik Sansthan, New Delhi. We acknowledge the support by Dr. Swaroop N, Ms. Sunitha BJ, Dr. Michael Baburaj, Mr. Sijil Joseph, Ms. Piyali Acharya, and Mr. Sarabjeet Singh in data collection and translation. Also, thanks to Ms. Suchandrima Chakraborty, Ms. Frost SD, Ms. Kavitha DL, and Dr. Ravi Prakash for their contribution to data analysis and initial draft report. We also extend our utmost gratitude to the team at St. John’s Research Institute, Bengaluru. Finally, we thank the field staff and the administration/ finance teams of Karnataka Health Promotion Trust, Bengaluru, and The Naz Foundation (India) Trust, New Delhi for their hard work and timely support for this study.

Data Availability

Yes, all data and materials from the this study are available without any restriction. However, to protect respondent privacy and other personally identifiable information from the qualitative nature of data, any interested researchers will be able to access the data by writing to corresponding authors Dr. Ramanaik (satya@khpt.org) or Karnataka Health Promotion Trust, Bengaluru, India (khptblr@khpt.org)

Funding Statement

This study was funded by the Indian Council of Medical Research (ICMR), New Delhi, India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

References

  • 1.UNAIDS. 2025 AIDS targets, Target-Setting, Impact and Resource Needs for the Global AIDS Response: Technical consultation on primary prevention, Geneva: Retrieved from file:///C:/Users/Aparna/Downloads/2025targets-PreventionMeeting_March2019.pdf. 2019.
  • 2.UNAIDS. Joint United Nations Programme on HIV/AIDS (UNAIDS), Reference; Retrieved from https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf. 2019.
  • 3.USAID. Country factsheets-India 2020; Accessed from https://www.unaids.org/en/regionscountries/countries/india. UNAIDS Country Director; 2021.
  • 4.NACO & ICMR. INDIA HIV Estimates 2019. In: Ministry of Health and Family Welfare GoIAfhngisdfIHEp, editor. New Delhi: NACO,; 2020. [Google Scholar]
  • 5.MoHFW, NACO. National Strategic Plan for HIV/AIDS and STI 2017–2024; Accessed from http://naco.gov.in/sites/default/files/Paving%20the%20Way%20for%20an%20AIDS%2015122017.pdf. 2017.
  • 6.UNAIDS. UNAIDS Prevention gap report; Retrieved from https://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf. 2016.
  • 7.NACO. Ministry of Health and Family Welfare (2019) Annual Report 2018–2019: National AIDS Control Organization (NACO) Retrieved from https://main.mohfw.gov.in/sites/default/files/24%20Chapter%20496AN2018-19.pdf. 2019.
  • 8.Saptarshi M. Section 377: Whose Concerns Does The Judgment Address?; Accessed from https://www.epw.in/node/152629/pdf Economic & Political weekly. 2018;53, Issue, No. 37(15).
  • 9.UNDP India. “Missing Pieces, HIV Related Needs of Sexual Minorities in India, National Stakeholder Consultation Report”, October 24–25, 2008, UNDP, New Delhi, India, Accessed from https://www.undp.org/content/dam/india/docs/msm_publications.pdf. 2008.
  • 10.Holland CE, Papworth E, Billong SC, Kassegne S, Petitbon F, Mondoleba V, et al. Access to HIV Services at Non-Governmental and Community-Based Organizations among Men Who Have Sex with Men (MSM) in Cameroon: An Integrated Biological and Behavioral Surveillance Analysis. PloS one. 2015;10(4):e0122881. doi: 10.1371/journal.pone.0122881 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chakrapani V, Newman PA, Shunmugam M, Mengle S, Varghese J, Nelson R, et al. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation. AIDS Patient Care STDS. 2015;29(10):569–77. doi: 10.1089/apc.2015.0143 [DOI] [PubMed] [Google Scholar]
  • 12.Chakrapani V, Shunmugam M, Rawat S, Baruah D, Nelson R, Newman PA. Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation. AIDS Patient Care STDS. 2020;34(2):92–8. doi: 10.1089/apc.2019.0237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Chakrapani V, Newman PA, Shunmugam M, Logie CH, Samuel M. Syndemics of depression, alcohol use, and victimisation, and their association with HIV-related sexual risk among men who have sex with men and transgender women in India. Global public health. 2017;12(2):250–65. doi: 10.1080/17441692.2015.1091024 [DOI] [PubMed] [Google Scholar]
  • 14.Shaw SY, Lorway RR, Deering KN, Avery L, Mohan HL, Bhattacharjee P, et al. Factors Associated with Sexual Violence against Men Who Have Sex with Men and Transgendered Individuals in Karnataka, India. PloS one. 2012;7(3):e31705. doi: 10.1371/journal.pone.0031705 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.WHO. WHO consultation on PrEP adherence: meeting report, USA: Retrieved from https://www.who.int/hiv/pub/prep/Prep-June2014.pdf. 2014.
  • 16.Reza-Paul S, Lazarus L, Doshi M, Hafeez Ur Rahman S, Ramaiah M, Maiya R, et al. Prioritizing Risk in Preparation for a Demonstration Project: A Mixed Methods Feasibility Study of Oral Pre-Exposure Prophylaxis (PREP) among Female Sex Workers in South India. PloS one. 2016;11(11):e0166889. doi: 10.1371/journal.pone.0166889 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Vaccher SJ, Gianacas C, Templeton DJ, Poynten IM, Haire BG, Ooi C, et al. Baseline Preferences for Daily, Event-Driven, or Periodic HIV Pre-Exposure Prophylaxis among Gay and Bisexual Men in the PRELUDE Demonstration Project. Frontiers in public health. 2017;5:341. doi: 10.3389/fpubh.2017.00341 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.AVERT. Global information and education on HIV and AIDS, Pre-Exposure Prophylaxis (Prep) For HIV Prevention. Retrieved from https://www.avert.org/professionals/hiv-programming/prevention/pre-exposure-prophylaxis. 2020.
  • 19.Ganju D, Saggurti N. Stigma, violence and HIV vulnerability among transgender persons in sex work in Maharashtra, India. Culture, health & sexuality. 2017;19(8):903–17. doi: 10.1080/13691058.2016.1271141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sharma P. Historical Background and Legal Status of Third Gender in Indian Society; Accessed from https://web.archive.org/web/20140203031618/ http://www.euroasiapub.org/IJRESS/dec2012/7.pdf. International Journal of Research in Economics & Social Sciences 2012. [Google Scholar]
  • 21.NACO. Targeted Interventions Under NACP III Operational Guidelines: Accessed from http://naco.gov.in/sites/default/files/NACP-III.pdf. 2007.
  • 22.QSR. NVivo qualitative data analysis software; QSR International Pty Ltd. Version 9, 2011. 2011.
  • 23.PrEP Watch. PrEP Watch: A snapshot of PrEP scale-up, registration and resources for India.Updated April 2020, Retrieved from https://www.prepwatch.org/country/india/. 2020.
  • 24.Kumar B, Ross MW. Sexual behaviour and HIV infection risks in Indian homosexual men: a cross-cultural comparison. International journal of STD & AIDS. 1991;2(6):442–4. [DOI] [PubMed] [Google Scholar]
  • 25.Chakrapani V, Newman PA, Shunmugam M, McLuckie A, Melwin F. Structural violence against Kothi-identified men who have sex with men in Chennai, India: a qualitative investigation. AIDS education and prevention: official publication of the International Society for AIDS Education. 2007;19(4):346–64. doi: 10.1521/aeap.2007.19.4.346 [DOI] [PubMed] [Google Scholar]
  • 26.Uthappa CK, Allam RR, Pant R, Pal S, Dinaker M, Oruganti G, et al. Pre-exposure prophylaxis: awareness, acceptability and risk compensation behaviour among men who have sex with men and the transgender population. HIV medicine. 2018;19(4):243–51. doi: 10.1111/hiv.12572 [DOI] [PubMed] [Google Scholar]
  • 27.Kennedy C FV. Pre-exposure prophylaxis for men who have sex with men: a systematic review, WHO/HIV/2014.9, Accessed from https://apps.who.int/iris/bitstream/handle/10665/128114/WHO_HIV_2014.9_eng.pdf?sequence=1&isAllowed=y. 2014.
  • 28.Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. New England Journal of Medicine. 2015;373(23):2237–46. [DOI] [PubMed] [Google Scholar]
  • 29.Nicol MR, Adams JL, Kashuba AD. HIV PrEP Trials: The Road to Success. Clinical investigation. 2013;3(3). doi: 10.4155/cli.12.155 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Caceres CF, Borquez A, Klausner JD, Baggaley R, Beyrer C. Implementation of pre-exposure prophylaxis for human immunodeficiency virus infection: progress and emerging issues in research and policy. J Int AIDS Soc. 2016;19(7(Suppl 6)):21108. doi: 10.7448/IAS.19.7.21108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.McKenney J, Chen A, Hoover KW, Kelly J, Dowdy D, Sharifi P, et al. Optimal costs of HIV pre-exposure prophylaxis for men who have sex with men. PloS one. 2017;12(6):e0178170. doi: 10.1371/journal.pone.0178170 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Chandhiok N, Joshi SN, Gangakhedkar R. Acceptability of oral and topical HIV chemoprophylaxis in India: implications for at-risk women and men who have sex with men. Sexual health. 2014;11(2):171–9. doi: 10.1071/SH13067 [DOI] [PubMed] [Google Scholar]
  • 33.Gomez EJ, Harris J. Political repression, civil society and the politics of responding to AIDS in the BRICS nations. Health policy and planning. 2016;31(1):56–66. doi: 10.1093/heapol/czv021 [DOI] [PubMed] [Google Scholar]
  • 34.Magno L, Silva L. Stigma and discrimination related to gender identity and vulnerability to HIV/AIDS among transgender women: a systematic review. 2019;35(4):e00112718. [DOI] [PubMed] [Google Scholar]
  • 35.UNAIDS. Eliminating discrimination in health care: Stepping stone towards ending the AIDS epidemic, UNAIDS Joint United Nations Programme on HIV/AIDS, Geneva Switzerland, Accessed from https://www.unaids.org/sites/default/files/media_asset/eliminating-discrimination-in-health-care_en.pdf. 2016.
  • 36.World Bank. India: community empowerment key to turning tide on HIV. In: The World Bank: news Accessed from https://www.worldbank.org/en/news/feature/2012/11/27/india-community-empowerment-key-to-turning-tide-on-hiv. 2012.
  • 37.WHO. Chapter 1: Community Empowerment, Implementing Comprehensive HIV-STI Programmes, Accessed from https://www.who.int/hiv/pub/sti/swit_chpt1.pdf?ua=1. 2016.
  • 38.Maslow AH. A theory of human motivation. Psychological Review. 1943;50(4):370–96. [Google Scholar]

Decision Letter 0

Dawn K Smith

18 Aug 2021

PONE-D-21-09058

Acceptability of PrEP among MSM and Transgender - qualitative findings from two metropolitan cities in India

PLOS ONE

Dear Dr. Ramanaik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please address the comments and suggestions of the reviewers and submit a revision. Improved clarity of sampling and analysis methods are especially needed.

Please submit your revised manuscript by Sep 30 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Dawn K. Smith

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please change potentially stigmatizing or outmoded terms such as "the transgenders" to or "transgenders" to currently accepted terminology such as "transgender people" or "transgender communities.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The study in the manuscript is a very relevant topic given the concentrated HIV/AIDS epidemic in India. It has the potential to inform the policies towards the framing of PrEP interventions. However, the authors may like to review the following to enhance its readability and rigors.

1. Please use the data on the latest status of the epidemic using sources of UNAIDS, Geneva as well as those from India

2. The introduction/methods/results/discussions may be limited to the aspects which are most relevant to the study objectives.

3. The manuscript needs to detail the limitations as standard.

Reviewer #2: 0- The authors have presented findings of a very pertinent research, which could be a crucial strategy for preventing new HIV infections in Asia and Pacific, and of course India, where the study has been done.

1- However, a few points in the article needs to be looked into.

- About the study's objective, and research question: The authors put three statements

{

It aimed to understand the barriers and enablers in acceptance of PrEP as a method of HIV prevention among MSM and Transgender in India. This study also attempts to provide plausible solutions and measures that would be required before rolling out the PrEP programs in India, by understanding and tailoring the program to the needs and concerns of the TG and MSM. It attempts to capture the experience and needs for

different MSM typologies and TG in two culturally different contexts in India.

}

Each of these could be potential research questions, which would require appropriate study design to answer meaningfully. For example, strategies to best tailor for a future programmatic implementation in India, can not come from a qualitative study only, rather, would require a few demonstration projects to best answer that question.

The methods, and findings of the study are on the qualitative aspect of the possible larger work that was perhaps done. Hence, it is desirable that the authors may try to give a specific objective, and a specific research question for the work that follows, in line with methods and results.

2- Authors have integrated the findings of the focus group discussion, and individual interview data. While this is not totally unacceptable, but it is leaving avenues of confusion. FGDs are best to give a glimpse of the novelties that are arising, while IDIs can be best used to triangulate the findings of the FGDs. In some cases, repeat FGDs are done to further substantiate the findings and merging themes.

Hence, method section may have details on chronology of the FGDs and IDIs, presentation of the findings separately for FGD and IDIs, and then trying to see if they are indeed triangulating.

3- Sampling strategy: Authors have very superficially mentioned that 'a mix of convenience and purposive sampling' was used to select the participants for FGD. Qualitative study does not mean that sampling strategy is not useful, or can be noted in passing. Since, this study presents cumulative findings of Delhi and Bangalore, it becomes very confusing when one tries to imagine how the samples were approached, and what was the sampling frame.

Hence, the authors should a) clearly delineate what do they meant by 'mix of convenience and purposive'?

b) They should give a clear account of sampling strategy, by describing the sampling frame. c) They should give numbers of MSM sites and TG sites in Delhi and Bangalore respectively (if targeted intervention sites were approached), and then how did they proceed to drill down upto the level of individuals in each city, in each site. c) Also give information on whether they were enrolled by a NGO, and was their any differential enrolment between TG and MSM-> this will help readers to appreciate many differences between MS and TG with regards to PrEP.

4- Eligibility criteria: While authors have given detail account of MSM, TGnj and TGh definitions, they have not presented anywhere, how exactly did they identify them? a) This needs to be given. b) Also within a given study site (eg targeted intervention) how MSM, and TGs were defined, and approached needs to be given.

5- TGh and TGnh were not much described in results later on, so authors may see if this additional distinction is a must requirement in introduction section?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Dr. Partha Haldar, Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Reviewer observations on the manuscript ID PONE - Copy - Copy.docx

PLoS One. 2023 Feb 22;18(2):e0281984. doi: 10.1371/journal.pone.0281984.r002

Author response to Decision Letter 0


3 Mar 2022

Response to Reviewers

***

Table 2. Specific observations

Section Line number Page number (Manuscript) Comments Response to Reviwer Comments

Introduction 46 4 There are updates in HIV burden estimates in India. The author may like to review, update and reference appropriately.

The suggested changes were incorporated and the citations are updated.

47 4 HIV prevalence is not an indicator to measure the impact of national/global AIDS response. The author might like to relate the impact with new infections, AIDS-related deaths, and survival and reference accordingly.

Agree, as suggested, the data on new infections and AIDS-related mortality were incorporated in the revised manuscript.

58 4 There are updates in HIV burden estimates in India. The author may like to review, update and reference appropriately.

The most recent data on HIV prevalence among MSM and Transgender population were included and related (USAID and NACO) citations were updated.

60-62 4 The size of MSM population is different from the official estimates of Govt of India. The author may bring that perspective also to provide a more comprehensive picture to the reader. Agree. A statement indicating the estimation of MSM population in India is much lesser than the actual number and this is because of the challenges associated with disclosure of identity and the estimation challenges are presented in the revised manuscript.

About the MSM and TG population in India 92-150 6-8 This whole section, while important in itself, appears redundant in the context of this manuscript. The Author may consider including the definition of MSM and TG used in this study in the methodology section and present this whole section about the MSM and TG in India as supplementary material. Agree. A definition of MSM and TG used in this study are presented in the methodology. The full section on “About the MSM and Transgender Community in India” is presented in the supplementary section.

Methodology 170 9 The study employed convenience and purposive sampling methods. The author may like to describe the study settings in brief to provide a perspective to the readers.

We have made slight changes in the sampling methods and elaborated the study setting to provide a better perspective to the readers.

171-172 9 The Author may define the distinct types of MSM and TGs recruited in this study here.

Yes, we have made the suggested changes and incorporated the relevant citations.

175 9 The manuscript not necessarily aims to present any findings by sub-typology of the MSM and TG. The author may consider focusing on the MSM and TG without any further reference to the specific sub-typologies.

Agree. The details of sub-typologies were removed and the findings now focus on MSM and TGs

177 10 May please put the interview guide in brief as a box either in the manuscript or put the detailed tool as supplementary material.

The specific themes used in the interview guide were elaborated in this section. But adding a table would cut the flow of this section. However, If the journal permits, we could add the detailed tool as supplementary material. Thank you for this feedback.

187-188 10 Please mention ‘study objectives and methods’ as areas of the training.

Incorporated these changes in the revised manuscript.

191-198 10 This paragraph details the study settings. However, it would be good to summarize them here and provide the details in the supplementary material perhaps.

We modified this paragraph and summarize the study setting in the revised manuscript.

222 12 The use of the word ‘paid’ may be reviewed as it breaks the flow of the sentence.

Sorry, this was a typo error, and the word ‘paid’ was removed in the revised manuscript.

Results 230-595 12-30 1. The author may consider being a bit more judicious while presenting the quotes and thematic areas. Only the areas which are directly and significantly related to the manuscript objectives may be presented. This will help the manuscript to be more focused and reader-friendly.

2. There is inconsistency in the presentation of the setting and speakers in the quotes. Sometimes, they have been presented by pseudonyms. Sometimes by the respondent ID. Sometimes, the locations have been mentioned. Sometimes, not. Consistency shall be ensured while

the presentation of presenting the setting and speakers in the quotes

3. The results in line 298 appears to be stigmatising a sub-group as inference is being written without mentioning any quote directly referring to the same. At the same time, the findings here doesn't add any significant findings in the context of the manuscript objective. The author may consider removing this result.

4. Consistency shall be established in results in different sections. In line 250, the results say both TG and MSMs had poor knowledge of PrEP. On the other hand, Table 2 specifically mentions as of TGs are well informed on PrEP. The author may like to review the results to ensure consistency in the presentation of results and concluding.

Thank you for this valuable feedback. We revisited the results sections and modified the quotes wherever necessary. In some places, more than one quote was presented earlier and it has been slightly changed now. We tried to retain the most relevant quotes and also, some writeups in the results were also modified based on this feedback.

Thank you for this important observation. As you suggested, we tried to present this more consistently. In the revised manuscript, we have included pseudonyms, participant sexual identity, age and geography. I think, this provides a better picture of the presented quotes and helps the readers to contextualize the informations.

This paragraph has been removed in the revised manuscript.

Your observations are correct. Line 250 is slightly modified now. In the revised manuscript, it says, “in both the sites, none of the MSM and TG people reported taking the PrEP ever”. After this sentence and also later in table 2, it was stated that “in both places, TGs displayed a better understanding of PrEP as compared to the MSM group”. This is the correct information.

Discussion 631-633 32 1. The statement that respondents clamoured for PrEP is inconsistent with the study finding of low awareness about PrEP. The author may like to rework the sentences.

2. The manuscript does not present any limitations. It is important to mention the same to provide perspectives to the readers. The word ‘clamoured’ is replaced with the word ‘inclined’. Basically, it says that most participants are motivated towards PrEP considering the challenges they have been facing in terms of correct and consistent use of condoms as HIV prevention strategy.

We presented the limitations in the revised manuscript. Thank you for this observation and feedback.

Decision Letter 1

Peter A Newman

7 Jun 2022

PONE-D-21-09058R1Acceptability of PrEP among MSM and Transgender Communities - qualitative findings from two metropolitan cities in IndiaPLOS ONE

Dear Dr. Ramanaik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Unfortunately, one of the initial reviewers was not available to assess the revisions made, and thus a new reviewer was assigned. This reviewer has very helpfully offered line-by-line suggestions for revising the manuscript. In light of the overall evaluation that the manuscript required professional proofreading in order to be comprehensible to an international readership, following these detailed suggested will be extremely helpful in improving readability. The suggestion about the placement of the limitations, and adding the further limitation indicated, is also in keeping with academic standards. Please when you make these revisions, indicate the location iof each revision in the text; this will expedite the editorial review process.

Please submit your revised manuscript by Jul 22 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Peter A. Newman, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #3: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: No

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #3: This paper provides qualitative data on the acceptability of PrEP in a diverse cohort of MSM (including those who have a westernised gay identity and those who are described by traditional Indian terms) and transgender women in two different settings in India. The participants in this study do not have access to PrEP, so they are responding to and intervention that has been described to them, rather than one they have personally used.

While I recognise that this paper has already undergone a round of review, I am recommending further revisions which I hope will add to the clarity of the paper and situate its findings more clearly in relation to other literature.

Please note that all the line numbers I reference are from the tracked changes version.

1. Firstly, I recommend professional copy editing for this manuscript, as there are numerous occasions where the wording choice is slightly jarring or the tense wrong. That said, I recognise that this is not always possible so I will endeavour to point out examples of wording choices and tenses.

2. I would strongly suggest that the umbrella term for the transgender respondents be changed to ‘transgender women’ (no capital ‘T’ needed for transgender). The use of ‘people’ initially made me think that both trans men and women – and possibly non-binary people – were included in the study, whereas it is all people with feminine identification (some who identify with the traditional term, hijra., and some who do not). If the authors feel it is inappropriate to use the term ‘women’ I bow to their superior understanding of the cultural context, but in my country when a trans person identifies as a woman it is considered respectful to call her a woman, regardless of what medical interventions she has or has not had.

3. Line 24, suggest ‘involving’ rather than ‘covering

4. Line 25 suggest ‘explored’ not ‘tired to explore

5. Line 32 – no semi colon after ‘acceptance’ – use comma

6. Line 39 – cut ‘makes a unique attempt to’ instead say ‘provides’

7. Line 42 – there;s a hanging ‘s’

8. Lines 67-70 ‘lesser’ should be less, and this line needs a citation

9. Line 78 – replace ‘sexual orientation’ with ‘gender identity

10. Line 172 – cut ‘was’

11. Line 175 ‘participants’’ – needs apostrophe

12. Lines 188-90 I suggest removing the phrase ‘typically have more effeminate mannerisms’ altogether, but if the author strongly disagree, then change the word ‘effeminate’ – which is pejorative – to ‘feminine’

13. Line 191. As I have recommended above, this paper will work better cross culturally if the term ‘transgenderer women’ is used throughout. At line 191, where there is a definition given, this could include ‘transgender women were reported male at birth but self-identify as women or feminine’

14. Line 203 – I suggest cutting the line that begins ‘A participatory approach’ – as this is usually understood to mean an approach where there is a stronger partnership between the researcher community and the researchers, from the inception of the project to the dissemination of results. What is described here is a considered approach that aims to ‘give back’ to research participants, which is laudable, but it is different to a participatory approach.

15. Line 225 no hyphen between two and days

16. Line 226 ‘included’ not ‘includes’

17. Line 265 – pseudonyms, not name

18. Line 226 can delete the line that begins ‘this additional consideration’ – extraneous, this is clear from the preceding line.

19. Line 302 – replace ‘comprehend’ with ‘misunderstood’

20. Line 303 – ‘the first introduction to THE CONCEPT OF PrEP’ – add the capitatlised words

21. Line 311 - After providing a briefing on PrEP (add italicised words)

22. Line 312 – delete ‘have’ , making it ‘the participants also’

23. Line 315 – replace ‘communities’ with ‘respondents’ or ‘participants’

24. Line 317 – ‘find’ should be ‘found’

25. Line 326 – The participants express a view that PrEP might reduce the need for HIV testing – was this misapprehension addressed with participants in the information provided, given that frequent testing remains important?

26. Line 327 – avoid the use of ‘shared’ use ‘reported’ or ‘suggested’

27. Line 341- text marked deleted – in this section a range of participants talk about sex where the lack of protection is forced by insertive partners, which reveal the profound power disparity between feminine or receptive sex partners and insertive partners. It seems important to me to keep some of this in the paper. I recommend cutting the section on recommendation regarding the general community, (484onwards) but keeping the section that relates to experiences of violence.

28. Line 455 – Don’t use ‘deviation’ – say ‘diversity’

29. Line 475 – ‘reported’ not ‘shared’

30. Line 478 – change ‘deteriorate’ to ‘exacerbate’

31. Line 487 change ‘are not’ to ‘is not’

32. Line 537 – it is not necessary to start taking PrEP 6 days before risk exposure (See data on ‘on demand’ PrEP by Molina) – this should be acknowledged in the text somewhere

33. Line 593 – ‘social pariah’s is a loaded term. How about ‘people of lower social status’ instead?

34. Line 660 – change ‘categorise’ to ‘distinguish’

35. Line 695 – rather than ;’nclined towards’ – ‘advocated strongly for’ PrEP

36. Line 697 – apostrophe in participant’s should be participants’

37. Line 713 ‘their traveling’ should be ‘the mobile’

38. Line 716-17 – this line takes the Australian study out of context (I am an author of it). The study was in the context of COVID-related changes and not broadly applicable to this context, excepting that is some instances people prefer to take PrEP medication irregularly, particularly if sex is irregular.

39. The paragraph beginning at line &31 should also address the misconception from the results that PrEP could reduce the need for HIV testing.

40. Line 745 – replace ‘This’ with ‘Discriminatory attitudes displayed by healthcare providers’

41. Line 755 ‘raised’ rather than ‘brought forth’

42. Line 805 – move the limitations to the end of the discussion, and commence with, “this study has some limitations’. After the line, ‘None of the participants have ever used PrEP’ add – ‘and they were dependent upon explanations from the research team to understand how it worked’

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Pradeep Kumar

Reviewer #3: Yes: Bridget Haire

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Feb 22;18(2):e0281984. doi: 10.1371/journal.pone.0281984.r004

Author response to Decision Letter 1


2 Aug 2022

Response to editor comments:

PONE-D-21-09058R1

Acceptability of PrEP among MSM and Transgender Communities - qualitative findings from two metropolitan cities in India

PLOS ONE

Dear Dr. Ramanaik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Unfortunately, one of the initial reviewers was not available to assess the revisions made, and thus a new reviewer was assigned. This reviewer has very helpfully offered line-by-line suggestions for revising the manuscript. In light of the overall evaluation that the manuscript required professional proofreading in order to be comprehensible to an international readership, following these detailed suggested will be extremely helpful in improving readability. The suggestion about the placement of the limitations, and adding the further limitation indicated, is also in keeping with academic standards. Please when you make these revisions, indicate the location of each revision in the text; this will expedite the editorial review process.

- We are grateful to the editorial team and the reviewers for their constructive feedback. This has greatly helped us to improve the quality of this paper. We have addressed each of the suggestions made by Reviewer 3 have also completed a professional proofreading in alignment with international readership. The limitation paragraph has been moved next to discussion section and all other suggested changes have been incorporated. All changes are made in track-change mode to expedite the review process.

Please submit your revised manuscript by Jul 22 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

- We have uploaded the above mentioned items as attachments along with the revised manuscript.

- If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Peter A. Newman, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Response to reviewers’ comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #3: (No Response)

________________________________________

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #3: Yes

________________________________________

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #3: N/A

________________________________________

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #3: Yes

________________________________________

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #3: No

________________________________________

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

- Thank you for your valuable feedback and the time spent to review this paper

Reviewer #3: This paper provides qualitative data on the acceptability of PrEP in a diverse cohort of MSM (including those who have a westernised gay identity and those who are described by traditional Indian terms) and transgender women in two different settings in India. The participants in this study do not have access to PrEP, so they are responding to and intervention that has been described to them, rather than one they have personally used.

While I recognise that this paper has already undergone a round of review, I am recommending further revisions which I hope will add to the clarity of the paper and situate its findings more clearly in relation to other literature.

- Thanks very much for your valuable feedback and the comments. We have tried our best to respond to all your comments.

Please note that all the line numbers I reference are from the tracked changes version.

1. Firstly, I recommend professional copy editing for this manuscript, as there are numerous occasions where the wording choice is slightly jarring or the tense wrong. That said, I recognise that this is not always possible so I will endeavour to point out examples of wording choices and tenses.

- Your feedback on the language is very helpful. We have addressed your feedback on the language and have also completed a professional proof-reading for language proficiency.

2. I would strongly suggest that the umbrella term for the transgender respondents be changed to ‘transgender women’ (no capital ‘T’ needed for transgender). The use of ‘people’ initially made me think that both trans men and women – and possibly non-binary people – were included in the study, whereas it is all people with feminine identification (some who identify with the traditional term, hijra., and some who do not). If the authors feel it is inappropriate to use the term ‘women’ I bow to their superior understanding of the cultural context, but in my country when a trans person identifies as a woman it is considered respectful to call her a woman, regardless of what medical interventions she has or has not had.

- We have used the terminology ‘transgender community’ or ‘transgender communities’ or transgender individuals which is the currently accepted terminology at an international level. We think this is more appropriate and acceptable in the local context. We would prefer to use this terminology instead of the term specifically referring to the community as ‘women’ or ‘men’.

3. Line 24, suggest ‘involving’ rather than ‘covering

- Agree. We have incorporated this change.

4. Line 25 suggest ‘explored’ not ‘tired to explore

- Agree. We have incorporated this change

5. Line 32 – no semi colon after ‘acceptance’ – use comma

- Agree. We have incorporated this change

6. Line 39 – cut ‘makes a unique attempt to’ instead say ‘provides’

- Agree. We have incorporated this change

7. Line 42 – there; s a hanging ‘s’

- Agree. We have incorporated this change

8. Lines 67-70 ‘lesser’ should be less, and this line needs a citation

- Agree. We have incorporated this change

9. Line 78 – replace ‘sexual orientation’ with ‘gender identity

- Agree. We have incorporated this change

10. Line 172 – cut ‘was’

- Agree. We have incorporated this change

11. Line 175 ‘participants’’ – needs apostrophe

- Agree. We have incorporated this change

12. Lines 188-90 I suggest removing the phrase ‘typically have more effeminate mannerisms’ altogether, but if the author strongly disagree, then change the word ‘effeminate’ – which is pejorative – to ‘feminine’

- Agree. We have incorporated this change

13. Line 191. As I have recommended above, this paper will work better cross culturally if the term ‘transgender women’ is used throughout. At line 191, where there is a definition given, this could include ‘transgender women were reported male at birth but self-identify as women or feminine’

- Agree. We have used transgender community.

14. Line 203 – I suggest cutting the line that begins ‘A participatory approach’ – as this is usually understood to mean an approach where there is a stronger partnership between the researcher community and the researchers, from the inception of the project to the dissemination of results. What is described here is a considered approach that aims to ‘give back’ to research participants, which is laudable, but it is different to a participatory approach.

- Agree. We have incorporated this change

15. Line 225 no hyphen between two and days

- Agree. We have incorporated this change

16. Line 226 ‘included’ not ‘includes’

- Agree. We have incorporated this change

17. Line 265 – pseudonyms, not name

- Agree. We have incorporated this change

18. Line 266 can delete the line that begins ‘this additional consideration’ – extraneous, this is clear from the preceding line.

- Agree. We have incorporated this change

19. Line 302 – replace ‘comprehend’ with ‘misunderstood’

- Agree. We have incorporated this change

20. Line 303 – ‘the first introduction to THE CONCEPT OF PrEP’ – add the capitalised words

- Agree. We have incorporated this change

21. Line 311 - After providing a briefing on PrEP (add italicised words)

- Agree. We have incorporated this change

22. Line 312 – delete ‘have’, making it ‘the participants also’

- Agree. We have incorporated this change

23. Line 315 – replace ‘communities’ with ‘respondents’ or ‘participants’

- Agree. We have incorporated this change

24. Line 317 – ‘find’ should be ‘found’

- Agree. We have incorporated this change

25. Line 326 – The participants express a view that PrEP might reduce the need for HIV testing – was this misapprehension addressed with participants in the information provided, given that frequent testing remains important?

- Yes. After every session, the misapprehensions and concerns that were raised by the participants were addressed and explained. One of the research team members was a medical doctor. He clarified questions related to HIV testing and other biomedical concerns.

26. Line 327 – avoid the use of ‘shared’ use ‘reported’ or ‘suggested’

- Agree. We have incorporated this change

27. Line 341- text marked deleted – in this section a range of participants talk about sex where the lack of protection is forced by insertive partners, which reveal the profound power disparity between feminine or receptive sex partners and insertive partners. It seems important to me to keep some of this in the paper. I recommend cutting the section on recommendation regarding the general community, (384onwards) but keeping the section that relates to experiences of violence.

- We agree with your suggestion and have retained the section suggested by you.

- The community’s recommendations on providing PrEP to other high-risk communities is relevant in the context of reducing HIV transmission. We consider that this is an important piece of information for policy makers to consider. We have therefore retained this recommendation as well.

28. Line 455 – Don’t use ‘deviation’ – say ‘diversity’

- Agree. We have incorporated this change

29. Line 475 – ‘reported’ not ‘shared’

- Agree. We have incorporated this change

30. Line 478 – change ‘deteriorate’ to ‘exacerbate’

- Agree. We have incorporated this change

31. Line 487 change ‘are not’ to ‘is not’

- Agree. We have incorporated this change

32. Line 537 – it is not necessary to start taking PrEP 6 days before risk exposure (See data on ‘on demand’ PrEP by Molina) – this should be acknowledged in the text somewhere

- Thank you for sharing this new information. We have used the standard information that was available at the time data was collected.

33. Line 593 – ‘social pariah’s is a loaded term. How about ‘people of lower social status’ instead?

- Agree. We have incorporated this change

34. Line 660 – change ‘categorise’ to ‘distinguish’

- Agree. We have incorporated this change

35. Line 695 – rather than ;’inclined towards’ – ‘advocated strongly for’ PrEP

- Agree. We have incorporated this change

36. Line 697 – apostrophe in participant’s should be participants’

- Agree. We have incorporated this change

37. Line 713 ‘their traveling’ should be ‘the mobile’

- Agree. We have incorporated this change

38. Line 716-17 – this line takes the Australian study out of context (I am an author of it). The study was in the context of COVID-related changes and not broadly applicable to this context, excepting that is some instances people prefer to take PrEP medication irregularly, particularly if sex is irregular.

- Agree. Thank you for this clarification.

39. The paragraph beginning at line &731 should also address the misconception from the results that PrEP could reduce the need for HIV testing.

- Agree. We have incorporated this change

40. Line 745 – replace ‘This’ with ‘Discriminatory attitudes displayed by healthcare providers’

- Agree. We have incorporated this change

41. Line 755 ‘raised’ rather than ‘brought forth’

- Agree. We have incorporated this change

42. Line 805 – move the limitations to the end of the discussion, and commence with, “this study has some limitations’. After the line, ‘None of the participants have ever used PrEP’ add – ‘and they were dependent upon explanations from the research team to understand how it worked’

- Agree. We have incorporated this change

________________________________________

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Pradeep Kumar

Reviewer #3: Yes: Bridget Haire

Attachment

Submitted filename: Response to reviweer comments_2nd Aug 2022.docx

Decision Letter 2

Peter A Newman

17 Aug 2022

PONE-D-21-09058R2Acceptability of PrEP among MSM and Transgender Communities - qualitative findings from two metropolitan cities in IndiaPLOS ONE

Dear Dr. Ramanaik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The authors have largely responded to the reviewer comments; however, in so doing they have introduced new errors into the manuscript that prevent it from being accepted in its current form.

1) The revisions are largely responsive to the reviewers' comments. However, this added statement in the Discussion section is simply not true; plus the citations the authors use in fact do the opposite of what they say. This is more problematic since this overstatement and sweeping characterization of many studies about trans people in India is used to claim the present study as unique. In fact, the authors need to cite these studies when they present their own results, and indicate various factors that have in fact already been identified in the published literature about PrEP use among MSM and among transgender people—not mischaracterize existing studies to claim the uniqueness of their own. 

Strangely, these 2 studies (13, 14) are cited as conflating MSM and trans people; but to the contrary, they demonstrate separate inquiries about PrEP in each population:

“In recent years, there has been an increase in the number of studies on that broach the subject of PrEP acceptability among MSM in India (13, 14). These studies do not distinguish transgender communities from the MSM population.”

13. Chakrapani V, Newman PA, Shunmugam M, Mengle S, Varghese J, Nelson R, et al. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation. AIDS Patient Care STDS. 2015;29(10):569-77.

14. Chakrapani V, Shunmugam M, Rawat S, Baruah D, Nelson R, Newman PA. Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation. AIDS Patient Care STDS. 2020;34(2):92-8.

2) The following statement in the abstract is erroneous. The authors claim to address these two populations as distinct, but then report as if HIV prevalence is the same; however, as the authors likely know, this is untrue. The sentence either needs to be re-worded or the different prevalence estimates among these populations indicated.

“Men who have sex with men (MSM) and transgender communities in India have 24-times higher HIV prevalence than the general population.”

Also, this information in the abstract conflicts with what is written in the Introduction:

“HIV prevalence among MSM (2.7%) and transgender community people (3.1%) is about 12 to 14 fold higher than the general population (0.22%) (4)

Both of these statements cannot be correct. 24 times higher? Or 12-14 fold higher?

3) I accept the authors’ response to Reviewer #3, and their use of the term transgender individual is fine, as is transgender community when not referring to an individual. However, the authors still move back and forth between capitalizing “Transgender” and using lower case “transgender”. Note that MSM is capitalized because it is an acronym; the word transgender should not be capitalized, as correctly indicated by the reviewer. It is now presented randomly in both formats, which is incorrect.

The problem with on and off capitalization of transgender starts in the abstract, but is repeated throughout the manuscript:

For ex.: Line 33: “However, when informed about PrEP, both MSM and Transgender communities expressed their willingness to use PrEP...."

But in the previous sentence, it is correctly written as transgender: “This study found that awareness and use of PrEP were minimal among the MSM and transgender communities.”

Then on p. 6: “There are very few studies on the acceptability of PrEP among MSM and transgender in India”

This is written without “individuals” or “communities”, just among “transgender”, which is incorrect.

4) DISCUSSION: This statement in the first sentence below does not logically correspond to the two following sentences. How can respondents “strongly advocate for PrEP” when “awareness was slight” and “knowledge of PrEP received mixed responses”? At least the first sentence needs to be re-written if you mean that AFTER they learned about PrEP, they were strongly supportive….

Also, there should be no apostrophe after participants in the 3rd sentence.

“Due to persistent risks associated with inconsistent use of condoms, most respondents have advocated strongly for PrEP. Very few among the study population had awareness of PrEP and its uses. Awareness was slightly higher more among the transgender communities. For many of the participants’ the first introduction to PrEP was through this study and knowledge of PrEP received mixed responses."

Additionally, it is important that the authors change this statement to indicate that it is not only due to “inconsistent condom use” that PrEP can be helpful for these communities. This statement implies that all sexual encounters are consensual and all HIV risk is an individual choice, as if to lay blame on individuals. In fact, several studies indicate high rates of sexual violence against both MSM and transgender people in India, and how that impacts on condom use--in addition to depression, alcohol use, etc. It is not merely choosing or not to use a condom. The following article shows that violence victimization, for one, is associated with lower rates of condom use. It also shows separate analyses among MSM and among transgender people, which provides yet another example that does not support the authors' claim that all previous HIV prevention research with transgender people in India fails to distinguish them from MSM. While their claim is true to an extent, they need to tone it down AND indicate examples of work (including the citation below, and references 13 and 14 above) that in fact has differentiated clearly between these two populations:

Venkatesan Chakrapani, Peter A. Newman, Murali Shunmugam, Carmen H. Logie & Miriam Samuel (2017) Syndemics of depression, alcohol use, and victimisation, and their association with HIV-related sexual risk among men who have sex with men and transgender women in India, Global Public Health, 12:2, 250-265, DOI: 10.1080/17441692.2015.1091024

5) The authors are unclear in their response about having the manuscript professionally proofread by someone fluent in English. While improved, it includes many errors in grammar and style, including formatting of citations. Since this journal does not have a proofreading stage, the authors must take this step themselves. For ex., in the first paragraph of the Introduction:

This sentence is incorrect. The way this is cited is wrong: " As per the recently released (2019) HIV estimation report 2019,..."

This sentence is missing a close parenthesis after (FSW … : Key populations including female sex workers (FSW, men who have sex with men (MSM), transgender community and persons who inject drugs (PWID)…

These comments present only a few of the instances showing the need for proofreading and corrections. The entire manuscript must be professionally proofread and corrected.

Please submit your revised manuscript by Oct 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Peter A. Newman, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Feb 22;18(2):e0281984. doi: 10.1371/journal.pone.0281984.r006

Author response to Decision Letter 2


24 Jan 2023

ONE-D-21-09058R2

Acceptability of PrEP among MSM and Transgender Communities - qualitative findings from two metropolitan cities in India

PLOS ONE

Dear Dr. Ramanaik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The authors have largely responded to the reviewer comments; however, in so doing they have introduced new errors into the manuscript that prevent it from being accepted in its current form.

1) The revisions are largely responsive to the reviewers' comments. However, this added statement in the Discussion section is simply not true; plus the citations the authors use in fact do the opposite of what they say. This is more problematic since this overstatement and sweeping characterization of many studies about trans people in India is used to claim the present study as unique. In fact, the authors need to cite these studies when they present their own results, and indicate various factors that have in fact already been identified in the published literature about PrEP use among MSM and among transgender people—not mischaracterize existing studies to claim the uniqueness of their own.

Strangely, these 2 studies (13, 14) are cited as conflating MSM and trans people; but to the contrary, they demonstrate separate inquiries about PrEP in each population:

“In recent years, there has been an increase in the number of studies on that broach the subject of PrEP acceptability among MSM in India (13, 14). These studies do not distinguish transgender communities from the MSM population.”

13. Chakrapani V, Newman PA, Shunmugam M, Mengle S, Varghese J, Nelson R, et al. Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation. AIDS Patient Care STDS. 2015;29(10):569-77.

14. Chakrapani V, Shunmugam M, Rawat S, Baruah D, Nelson R, Newman PA. Acceptability of HIV Pre-Exposure Prophylaxis Among Transgender Women in India: A Qualitative Investigation. AIDS Patient Care STDS. 2020;34(2):92-8.

Agree. We have incorporated the changes accordingly. These studies cover two different groups and are pioneer studies in investigating about PrEP acceptability in transgender women and MSMs separately in India.

Earlier the statement tried to highlight that often there is ambiguity and over representation of transgender by including MSM, transgender men, transgender women and female sex workers under one umbrella. However, particularly these two studies clearly inquire about two different groups. Changes have been accordingly.

2) The following statement in the abstract is erroneous. The authors claim to address these two populations as distinct, but then report as if HIV prevalence is the same; however, as the authors likely know, this is untrue. The sentence either needs to be re-worded or the different prevalence estimates among these populations indicated.

“Men who have sex with men (MSM) and transgender communities in India have 24-times higher HIV prevalence than the general population.”

Also, this information in the abstract conflicts with what is written in the Introduction:

“HIV prevalence among MSM (2.7%) and transgender community people (3.1%) is about 12 to 14 fold higher than the general population (0.22%) (4)

Both of these statements cannot be correct. 24 times higher? Or 12-14 fold higher?

Agree, have incorporated the correct estimation. It is around 15-17 fold higher. Also, the figures for MSM have been updated in the introduction, referring to the latest data from HIV surveillance report 2021.

https://www.unaids.org/en/regionscountries/countries/india (same reference) only numbers updated

3) I accept the authors’ response to Reviewer #3, and their use of the term transgender individual is fine, as is transgender community when not referring to an individual. However, the authors still move back and forth between capitalizing “Transgender” and using lower case “transgender”. Note that MSM is capitalized because it is an acronym; the word transgender should not be capitalized, as correctly indicated by the reviewer. It is now presented randomly in both formats, which is incorrect.

The problem with on and off capitalization of transgender starts in the abstract, but is repeated throughout the manuscript:

For ex.: Line 33: “However, when informed about PrEP, both MSM and Transgender communities expressed their willingness to use PrEP...."

But in the previous sentence, it is correctly written as transgender: “This study found that awareness and use of PrEP were minimal among the MSM and transgender communities.”

Agree, incorporated the changes, made it uniform as ‘transgender communities’ or ‘transgender individual’ as per the context

Then on p. 6: “There are very few studies on the acceptability of PrEP among MSM and transgender in India”

This is written without “individuals” or “communities”, just among “transgender”, which is incorrect.

Agree. We have incorporated the changes, added ‘communities’ while referring to transgender community

4) DISCUSSION: This statement in the first sentence below does not logically correspond to the two following sentences. How can respondents “strongly advocate for PrEP” when “awareness was slight” and “knowledge of PrEP received mixed responses”? At least the first sentence needs to be re-written if you mean that AFTER they learned about PrEP, they were strongly supportive….

Also, there should be no apostrophe after participants in the 3rd sentence.

Agree, we stand corrected and have made the changes.

“Due to persistent risks associated with inconsistent use of condoms, most respondents have advocated strongly for PrEP. Very few among the study population had awareness of PrEP and its uses. Awareness was slightly higher more among the transgender communities. For many of the participants’ the first introduction to PrEP was through this study and knowledge of PrEP received mixed responses."

Additionally, it is important that the authors change this statement to indicate that it is not only due to “inconsistent condom use” that PrEP can be helpful for these communities. This statement implies that all sexual encounters are consensual and all HIV risk is an individual choice, as if to lay blame on individuals. In fact, several studies indicate high rates of sexual violence against both MSM and transgender people in India, and how that impacts on condom use--in addition to depression, alcohol use, etc. It is not merely choosing or not to use a condom. The following article shows that violence victimization, for one, is associated with lower rates of condom use. It also shows separate analyses among MSM and among transgender people, which provides yet another example that does not support the authors' claim that all previous HIV prevention research with transgender people in India fails to distinguish them from MSM. While their claim is true to an extent, they need to tone it down AND indicate examples of work (including the citation below, and references 13 and 14 above) that in fact has differentiated clearly between these two populations:

Venkatesan Chakrapani, Peter A. Newman, Murali Shunmugam, Carmen H. Logie & Miriam Samuel (2017) Syndemics of depression, alcohol use, and victimisation, and their association with HIV-related sexual risk among men who have sex with men and transgender women in India, Global Public Health, 12:2, 250-265, DOI: 10.1080/17441692.2015.1091024

Agree. As correctly pointed out ‘inconsistent condom use’ is only one of the factors but more importantly experiences of violence put the MSM and TG communities at a greater risk of HIV infection. This is added in the text and another research article (Shaw et. Al 2012) has been referred to inform the same, in addition to Chakrapani’s paper (2017).

5) The authors are unclear in their response about having the manuscript professionally proofread by someone fluent in English. While improved, it includes many errors in grammar and style, including formatting of citations. Since this journal does not have a proofreading stage, the authors must take this step themselves. For ex., in the first paragraph of the Introduction:

This sentence is incorrect. The way this is cited is wrong: " As per the recently released (2019) HIV estimation report 2019,..."

Agree. We have corrected the sentence

This sentence is missing a close parenthesis after (FSW … : Key populations including female sex workers (FSW, men who have sex with men (MSM), transgender community and persons who inject drugs (PWID)…

Agree. We have corrected the sentence

These comments present only a few of the instances showing the need for proofreading and corrections. The entire manuscript must be professionally proofread and corrected.

Please submit your revised manuscript by Oct 01 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

• A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

• A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

• An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Peter A. Newman, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Response to Editor Comments_PLOS ONE_22 Jan 2023.docx

Decision Letter 3

Peter A Newman

7 Feb 2023

Acceptability of PrEP among MSM and transgender communities - qualitative findings from two metropolitan cities in India

PONE-D-21-09058R3

Dear Dr. Ramanaik,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Peter A. Newman, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Peter A Newman

10 Feb 2023

PONE-D-21-09058R3

Acceptability of PrEP among MSM and transgender communities - qualitative findings from two metropolitan cities in India

Dear Dr. Ramanaik:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Peter A. Newman

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    Attachment

    Submitted filename: Reviewer observations on the manuscript ID PONE - Copy - Copy.docx

    Attachment

    Submitted filename: Response to reviweer comments_2nd Aug 2022.docx

    Attachment

    Submitted filename: Response to Editor Comments_PLOS ONE_22 Jan 2023.docx

    Data Availability Statement

    Yes, all data and materials from the this study are available without any restriction. However, to protect respondent privacy and other personally identifiable information from the qualitative nature of data, any interested researchers will be able to access the data by writing to corresponding authors Dr. Ramanaik (satya@khpt.org) or Karnataka Health Promotion Trust, Bengaluru, India (khptblr@khpt.org)


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES